Pharmaceutical Among last week’s news of interest was Danish diabetes care giant Novo Nordisk’s acquisition of a small UK-based biotech firm Ziylo. Regulatory news included a blow for Allergan when the US Food and Drug Administration issued a complete response letter on its uterine fibroids therapy Esmya while Shire was rewarded with approval of its novel hereditary angioedema drug Takhzyro. On the research front, Novo Nordisk pleased when it presented positive results from a Phase IIIa study of its oral diabetes candidate semaglutide. 26 August 2018